NCT00270296View on ClinicalTrials.gov

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

730

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

September 30, 2010

Conditions
HIV Infections
Interventions
DRUG

Trizivir

300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily

DRUG

Lamivudine/Zidovudine

150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily

DRUG

Lopinavir/Ritonavir

400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily

DRUG

Nevirapine

200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily

Trial Locations (4)

Unknown

Princess Marina Hosp., BHP Study Clinic, Gaborone Shapiro CRS, Gaborone

Athlone Hosp., BHP Study Clinic, Lobatse Shapiro CRS, Lobatse

Deborah Reteif Hosp., BHP Study Clinic, Mochudi Shapiro CRS, Mochudi

Scottish Livingstone Hosp., BHP Study Clinic, Molepolole Shapiro CRS, Molepolole

All Listed Sponsors
collaborator

Harvard School of Public Health (HSPH)

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00270296 - Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV | Biotech Hunter | Biotech Hunter